Scancell was founded in 1996 and is headquartered in Nottingham, United Kingdom. Scancell main 2 cancer vaccine programmes are ImmunoBody® and Moditope®. Scancells first vaccine SCIB1 is showing positive results for patients in resected Stage II or III disease, it is used to treat melanoma. Scancell Limited operates as a subsidiary of Scancell Holdings PLC.